MENU
Anatomy
Anesthesiology
Biochemistry
Biomedical Informatics
Biophysics
Cell Biology
Clinical Cases
Dentistry
Dermatovenerology
Emergency Medicine
Family Medicine
Forensic Medicine
Gynecology and Obstetrics
Histology and Embryology
History of Medicine
Human Genetics
Hygiene
Infectious Diseases
Internal Medicine
Medical Deontology and Philosophy
Medical Psychology
Microbiology and Immunology
Neurology
Occupational Medicine
Oncology
Ophthalmology
Orthopaedics
Otorhinolaryngology
Pathology
Pathophysiology
Pediatrics
Pharmacology and Experimental Toxicology
Physical and Rehabilitation Medicine
Physiology
Psychiatry
Radiology
Social Medicine
Surgery
Toxicology
Research papers
Clinical research paper
Preclinical research paper
Sponsored articles
Archive » 2010 » 1 » | Archive » Medical field » Fields » Internal Medicine »

Biologic Drugs in Asthma Treatment

 
Abstract:

This post is also available in: enEnglish slSlovenščina (Slovenian)

Development of the new antiasthmatic drugs is directed above all in the synthesis of theinhibitors of the proinflammatory cytokines and IgE antibodies. Several biologic drugs are tested for this purpose; most common of them are monoclonal antibodies or modified recep­tors. Experiments were also done with antiinflammatory cytokines, chemokine inhibitors, antilymphocytic antibodies, cell adhesion blockers and CpG oligonucleotides. The most promis­ing drugs are those directed against interleukines IL-4, IL-5, IL-13, cytokine TNFa and IgE immunoglobulin. Humanized monoclonal antibody directed against immunoglobulin E bind­ing site is the only biologic drug which is already used in the asthma treatment. Better under­standing of the molecular mechanisms of asthma leads to the identification of the new therapeutic targets.

Authors:
Berce Vojko, Krajnc Ivan, Potočnik Uroš

Keywords:
monoclonal antibodies, proinflammatory cytokines, anti IgE, omalizumab

Cite as:
Med Razgl. 2010; 49: 11–8.

Download PDF >>
© 2021 Društvo Medicinski razgledi | Na vrh strani / To top ↑